Among them, 70% of BC patients have hormone-dependent estrogen receptor α (ERα or ER) positive tumors defined as luminal A and B subtypes [2–4], and estrogen (E2) plays a major role in the tumor initiation and progression [5–7]. Here, ESR1 is linked to breast cancer.